Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

192 results about "Immunostimulant" patented technology

Immunostimulants, also known as immunostimulators, are substances (drugs and nutrients) that stimulate the immune system by inducing activation or increasing activity of any of its components. One notable example is the granulocyte macrophage colony-stimulating factor.

Botanical extract compositions and methods of use

A composition having phytoestrogenic and anti-cancer activity is described. The composition comprises wogonin, isoliquiritigenin, coumestrol, their pharmaceutically acceptable salts or esters, their selectively substituted analogs, or combinations thereof. The compositions may also include an anti-cancer agent and / or an immune stimulant. A method for treating or preventing cancer or an estrogen-related disorder includes administering a therapeutically effective amount of the compositions is described. The compositions are particularly useful in the treatment of hormone-related cancers.
Owner:ACTIVEPHYTO TECH LTD

Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines

InactiveUS20120052080A1Enhance or improve the prophylactic effect(s) of another therapyShorten the durationNervous disorderCell receptors/surface-antigens/surface-determinantsMedicineImmunostimulant
Provided herein are interleukin-13 receptor α2 peptide-based brain cancer vaccines and methods for treating and vaccinating against brain cancer comprising administering to patients in need thereof interleukin-13 receptor α2 peptide-based brain cancer vaccines. Also provided herein are regimens comprising interleukin-13 receptor α2 peptides and at least one additional peptide and / or immunostimulant.
Owner:UNIVERSITY OF PITTSBURGH

Human immune therapies using a CD27 agonist alone or in combination with other immune modulators

Methods of inducing T cell proliferation and expansion in vivo for treating conditions wherein antigen-specific T cell immune response are therapeutically desirable such as cancer, infection, inflammation, allergy and autoimmunity and for enhancing the efficacy of vaccines are provided. These methods comprise the administration of at least one CD27 agonist, preferably an agonistic CD27 antibody, alone or in association with another moiety such as immune stimulant or immune modulator such as an anti-CD40, OX-40, 4-IBB, or CTLA-4 antibody or an agent that depletes regulatory cells, or a cytokine. These mono and combination therapies may also optionally include the administration of a desired antigen such as a tumor antigen, an allergen, an autoantigen, or an antigen specific to an infectious agent or pathogen against which a T cell response (often CD8+) is desirably elicited.
Owner:UNIV OF SOUTHAMPTON

Interferon immunotherapy

A method for reducing the recurrence of a resectable malignant tumor includes administering an immunostimulatory dosage of an α-interferon composition, then surgically resecting the malignant tumor. A method for treating a human patient having a non-resectable malignant tumor includes administering an immunostimulatory dosage of an α-interferon composition to the patient and treating the patient with effective non-surgical medical methodologies to diminish the tumor. An article of manufacture combines an α-interferon composition within a packaging material and a package label or insert indicating that administration of an immunostimulatory dosage of an α-interferon composition followed by surgical resection of a malignant tumor can be effective for treating a human patient having the malignant tumor.
Owner:MAYO FOUND FOR MEDICAL EDUCATION & RES

Double-stranded locked nucleic acid compositions

Immunostimulatory agents, including nucleic acids having one or more than one locked nucleic acid (LNA) nucleosides are provided. The nucleic acids may further comprise CpG motifs. The nucleic acids may be double stranded, and may comprise dsRNA.
Owner:NVENTA BIOPHARMACEUTICALS CORP

RNA cancer vaccines

PendingUS20190351040A1Balanced immune responseOrganic active ingredientsAntibody ingredientsTetanusAdjuvant
The disclosure relates to cancer ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines. In particular, the disclosure relates to concatemeric mRNA cancer vaccines encoding several cancer epitopes on a single mRNA construct, i.e. poly-epitope mRNA constructs or poly-neo-epitope constructs. The disclosure further relates to p53 and KRAS mutations, as well as incorporation of immune enhancers such as STING, e.g. mRNA constructs further encoding an immune stimulator or adjuvant. The disclosure further relates to inclusion of universal T cell epitopes, such as tetanus or diphtheria toxins to elicit an enhanced immune response.
Owner:MODERNATX INC

Immunostimulatory, Covalently lipidated oligonucleotides

Covalently lipidated oligonucleotides comprising the CpG dinucleotide unit, or an analogue thereof, may be used as immunostimulatory agents to protect against a disease caused by a cancer cell or a pathogen, either alone or in conjunction with immunogens and / or non-immunological agents. Lipidated oligonucleotides with special backbones, lipidated oligonucleotides with fewer than eight nucleotides, and lipidated oligonucleotides comprising a plurality of CpG dinucleotide-containing segments connected by a long internucleoside linkage are of particular interest. These compounds are also novel per se.
Owner:ONCOTHYREON

Immunostimulatory agents in botanicals

InactiveUS20050002962A1Improved immunostimulatory activityHigh activityBiocideLichen medical ingredientsRed CloverBlack cohosh
A melanin preparation as an immunostimulatory agent from at least one of the following botanicals: Echinacea, American ginseng, black walnut, green tea, Parthenium integrifolium, Korean ginseng, alfalfa sprouts, ginger, goldenseal, red clover, dandelion, black cohosh, licorice, chamomile, milk thistle, alfalfa, horsetail, astragalus, gotu kola, feverfew, valerian, hawthorn, rosemary, saw palmetto, ephedra, pau d'arco, ginkgo, garlic, St. John's wort, Agaricus bisporus (common mushroom), Agaricus bisporus brown strain (portabella mushroom), Lentinus edodes (shiitake mushroom) or Boletus edulis (porcini mushroom). Also disclosed is methods of treating a subject requiring immune mediation comprising administering to said subject a therapeutically effective amount of a melanin preparation from any one of the following botanicals: Echinacea, American ginseng, black walnut, green tea, Parthenium integrifolium, Korean ginseng, alfalfa sprouts, ginger, goldenseal, red clover, dandelion, black cohosh, licorice, chamomile, milk thistle, alfalfa, horsetail, astragalus, gotu kola, feverfew, valerian, hawthorn, rosemary, saw palmetto, ephedra, pau d'arco, ginkgo, garlic, St. John's wort, Agaricus bisporus (common mushroom), Agaricus bisporus brown strain (portabella mushroom), Lentinus edodes (shiitake mushroom), Boletus edulis (porcini mushroom).
Owner:UNIVERSITY OF MISSISSIPPI

Soluble T cell receptor

The present invention relates to a recombinant soluble T cell receptor. The T cell receptor (TCR) is refolded and comprises a recombinant TCR alpha or gamma chain extracellular domain having a first heterologous C-terminal dimerisation peptide; and a recombinant TCR beta or delta chain extracellular domain having a second C-terminal dimerisation peptide which is specifically heterodimerised with the first dimerisation peptide to form a heterodimerisation domain, which may be a coiled coil domain. The invention also provides nucleic acid sequences encoding the recombinant TCR and a method for producing the recombinant TCR. The TCR may be labelled with a detectable label so as to enable the detection of specific MHC-peptide complexes. Alternatively, it can be linked to a therapeutic agent such as a cytotoxic agent or an immunostimulating agent so as to deliver such an agent to the site of a specific MHC-peptide complex.
Owner:JAKOBSEN BENT KARSTEN +4

Short immunomodulatory oligonucleotides

The invention relates to modulation of the immune system. More particularly, the invention relates to modulating the immune system through the use of oligonucleotide-derived compounds. The invention provides immunostimulatory agents that are less expensive to make than existing immunostimulatory oligonucleotides. The immunostimulatory agents according to the invention can, in preferred embodiments, cause immune stimulation across species lines.
Owner:IDERA PHARMA INC

Imine-forming polysaccharide adjuvants and immunostimulants

The present invention relates to polysaccharide conjugates that comprise: a polysaccharide that binds to surface-receptors present on Antigen Presenting Cells, conjugated to one or more compounds having stable carbonyl groups covalently attached, either directly or via a bifunctional linker. The conjugates are useful as immuno-stimulants and adjuvants.
Owner:GALENICA PHARMA

Human immune therapies using a cd27 agonist alone or in combination with other immune modulators

InactiveUS20130336976A1Promotes strong expression of 4-1BBImprove responseAntibacterial agentsAntimycoticsIMMUNE STIMULANTSCD8
Methods of inducing T cell proliferation and expansion in vivo for treating conditions wherein antigen-specific T cell immune response are therapeutically desirable such as cancer, infection, inflammation, allergy and autoimmunity and for enhancing the efficacy of vaccines are provided. These methods comprise the administration of at least one CD27 agonist, preferably an agonistic CD27 antibody, alone or in association with another moiety such as immune stimulant or immune modulator such as an anti-CD40, OX-40, 4-1BB, or CTLA-4 antibody or an agent that depletes regulatory cells, or a cytokine. These mono and combination therapies may also optionally include the administration of a desired antigen such as a tumor antigen, an allergen, an autoantigen, or an antigen specific to an infectious agent or pathogen against which a T cell response (often CD8+) is desirably elicited.
Owner:UNIV OF SOUTHAMPTON

Immune Response Stimulating Composition Comprising Nanoparticles Based on a Methyl Vinyl Ether-Maleic Acid Copolymer

ActiveUS20070224225A1Good bioadhesive characteristicEasy to producePowder deliveryNanomedicineAntigenCross-link
The composition for stimulating an immune response in a subject comprises methyl vinyl ether and maleic anhydride copolymer-based nanoparticles. Said nanoparticles may further contain an allergen or an antigen and / or an immunostimulating agent, which may be contained inside said nanoparticles and / or at least partially coating the surface of said nanoparticles, and optionally a cross-linking agent. The immune response stimulating composition is useful as an adjuvant in immunotherapy and vaccines.
Owner:INNOUP FARMA

Compositions and methods for delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse

The present disclosure provides compositions and methods for the delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse. The compositions comprise (i) a structure comprising an injectable polymer or scaffold comprising pores; (ii) lymphocytes disposed within the structure, (iii) at least one lymphocyte-adhesion moiety associated with the structure; and (iv) at least one lymphocyte-activating moiety associated with the structure, and optionally an immune stimulant.
Owner:FRED HUTCHINSON CANCER RES CENT

Microparticulate systems for the oral administration of biologically active substances

The present invention relates to gastroresistant and enterosoluble microparticulate systems for the encapsulation of biologically active substances selected from: flavonoids, vitamins, antioxidants, immunostimulants, starchy and non-starchy polysaccharides, probiotics, prebiotics, intestinal trophism regulators, oligoelements, enzymes and bioactive peptides. Such microparticulate systems allow the administration of the aforementioned nutraceutic substances to animals such as porcines, bovines, caprines, ovines, equids, canids, felines, camelids, lagomorphs, rodents, fowl, and other mammals, including humans, fish and crustaceans, increasing the bioavailability.
Owner:UNIV DEGLI STUDI DI PARMA +1

Detection/Measurement Of Malaria Infection Disease Utilizing Natural Immunity By Hemozoin Induction, Screening Of Preventative Or Therapeutic Medicine For Malaria Infection Disease, And Regulation Of Natural Immunity Induction

The instant invention is to provide a method for detecting and measuring malaria infection utilizing the induction by hemozoin (HZ); a method for screening a vaccine for malaria infection and a preventative or therapeutic agent for malaria infection using the method for detecting and measuring; and a means for regulating the induction of innate immunity using the HZ, synthetic HZ, or derivatives thereof as an adjuvant or immunostimulant. Malaria infection is detected and measured of by detecting and measuring HZ-induced, TLR9-mediated, and MyD88-dependent innate immune activity. The detection and measurement of malaria infection can be used to diagnose malaria infection. The method for detecting and measuring is also used for screening a vaccine for malaria infection and a preventative or therapeutic agent for malaria infection. Further, HZ, synthetic HZ, or derivatives thereof are used as an adjuvant or immunostimulant to regulate HZ-induced innate immune induction.
Owner:OSAKA UNIV

Potent immunostimulatory extracts from microalgae

Immunostimulatory compounds can be extracted from microalgae or algae using various procedures. The resulting preparations exhibit extremely potent immunostimulatory activity. The extraction of these immunostimulatory agents is dependent on the solvent used and the extraction temperature. These preparations are potentially useful as a botanical or pharmaceutical preparation to improve immune function.
Owner:UNIVERSITY OF MISSISSIPPI

Using Targeted Radiotherapy (TRT) to Drive Anti-Tumor Immune Response to Immunotherapies

The disclosed method of treating a malignant solid tumor in a subject includes the steps of administering to the subject an immunomodulatory dose of a radioactive phospholipid ether metal chelate, a radiohalogenated phospholipid ether, or other targeted radiotherapy (TRT) agent that is differentially retained within malignant solid tumor tissue, and either (a) performing in situ tumor vaccination in the subject by introducing into at least one of the malignant solid tumors one or more agents capable of stimulating specific immune cells within the tumor microenvironment, or (b) performing immunotherapy in the subject by systemically administering to the subject an immunostimulatory agent, such as an immune checkpoint inhibitor. In a non-limiting example, the radioactive phospholipid ether metal chelate or radiohalogenated phospholipid ether has the formula:wherein R1 comprises a chelating agent that is chelated to a metal atom, wherein the metal atom is an alpha, beta or Auger emitting metal isotope with a half-life of greater than 6 hours and less than 30 days, or wherein R1 comprises a radioactive halogen isotope. In one such embodiment, a is 1, n is 18, m is 0, b is 1, and R2 is —N+(CH3)3.
Owner:WISCONSIN ALUMNI RES FOUND

Immunostimulatory, covalently lipidated oligonucleotides

Covalently lipidated oligonucleotides comprising the CpG dinucleotide unit, or an analogue thereof, may be used as immunostimulatory agents to protect against a disease caused by a cancer cell or a pathogen, either alone or in conjunction with immunogens and / or non-immunological agents.Lipidated oligonucleotides with special backbones, lipidated oligonucleotides with fewer than eight nucleotides, and lipidated oligonucleotides comprising a plurality of CpG dinucleotide-containing segments connected by a long internucleoside linkage are of particular interest. These compounds are also novel per se.
Owner:ONCOTHYREON

Compositions and methods for treatment of tumors and metastatic diseases

Compositions and methods are provided which can be utilized in active immunization as a prophylactic treatment or a therapeutic treatment for tumors. The compositions are employed as injectable tumor vaccines or as preparations for intratumoral administration and are capable of stimulating immune responses to specific tumor antigens. The tumor vaccines are composed of an antigenic cellular material including a plurality of inactivated tumor cells or tumor cell portions, a depot material, and an immunostimulant adsorbed to the depot material. The depot material with absorbed immunostimulant is mixed with the tumor cells or tumor cell portions to form the vaccine compositions. The preparations for intratumoral administration include the depot material adsorbed immunostimulant without the antigenic cellular material. The immunostimulant adsorbed to the depot material permits release of biologically active quantities of the immunostimulant over a period of time rather than all at once.
Owner:FRANK W FALKENBERG

Method for preparing immunostimulant for fish

The invention relates to a method for preparing an immunostimulant for fish, which belongs to the technical field of aquatic formula feeds. The method is characterized in that the method comprises the steps of taking rhubarb extract, humifuse euphorbia herb, hairyvein agrimonia herb and bud, red-knees herb, glutamine, potassium dihydrogen phosphate and the like, as well as a carrier; fully mixing all components, then smashing and preparing into dry powder. The method has the advantages of stable sources of raw materials, simple preparation, extensive material obtainment and low cost; the immunostimulant is prepared from the fish immunization mechanical and can not only supplement Chinese herbal medicine, but also supplement western medicine of glutamine dipeptide; and the immunostimulant conditions stress of the fish through the combination of Chinese and western medicines and appropriately supplements the loss of Na+, K+ caused by the stress for controlling the stress of the fish. When in use, the immunostimulant can improve the fish immune and the antioxidant capacity, improve the high density resistance of the fish and the resistance to aeromonase hydrophila infection and promote the growth of the fish.
Owner:FRESHWATER FISHERIES RES CENT OF CHINESE ACAD OF FISHERY SCI +3

Manganese dioxide nanometer adjuvant and preparation method and application thereof

The invention provides a manganese dioxide nanometer material. The manganese dioxide nanometer material comprises manganese dioxide nanoparticles and carried matter, wherein the carried matter is compounded onto the surface of the manganese dioxide nanoparticle; the carried matter comprises oligonucleotide CpG and / or antigen; the antigen comprises protein antigen and / or polypeptide antigen. The provided manganese dioxide nanometer material has the advantages that the immunostimulation function of an immunologic adjuvant CpG is greatly improved, the immunity protection function of vaccine is improved, and the inherent defect of effective improving of immune reaction by a large amount of CpG because the oligonucleotide CpG is used as an immunologic stimulant and cannot easily enter the body lymph glands is solved; the manganese dioxide nanometer material is used as a vaccine adjuvant, and can carry the antigen, especially the protein antigen, so that the intake on the antigen by the immune cells in the lymph glands is effectively improved, and the immunogenicity of the antigen is improved; the nanometer adjuvant can be biologically degraded, and can be gradually degraded into manganese ions (Mn<2+>) under the weak acid environment, such as lysosome, and the manganese ions are finally discharged out of the human body.
Owner:SUZHOU INNOVATIVE BIOMATERIALS & PHARM CO LTD

In Vivo Enhancement of Immune System Recognition of Neoplasms Following Treatment with an Oncolytic Virus or Gene Therapy Vector

This invention provides novel methods of treating or alleviating neoplasms and enhancing the efficacy of oncolytic viruses by administering an oncolytic virus to a mammal suffering from a neoplasm and subsequently administering an immunostimulant. The invention also provides methods of increasing immunorecognition of neoplastic cells.
Owner:ONCOLYTICS BIOTECH

Immunopotentiators in thermotherapy for cancer

InactiveUS20050013875A1Good effectExcellent cancer therapeutic effectHeavy metal active ingredientsBiocideLymphatic SpreadSide effect
The present invention relates to an immunostimulator in hyperthermia of cancer, which contains a heat shock protein-inducing compound such as geranylgeranyl acetone, etc. The immunostimulator of the present invention can effectively regress tumor tissue that is difficultly treated by hyperthermia alone by combining with the hyperthermia, and also, metastasis of cancer can be effectively inhibited substantially without side effect.
Owner:TTC

Production of fungal extracellular immune stimulating compounds

A process is described for the production of an immunostimulant by submerged cultivation of Lentinus edodes in which mycelium from agar plates or a fermentation broth is added to a liquid medium in a shake flask or a bioreactor containing nutrients such as malt extract, yeast extract, peptone and glucose having access to air or to which air is added, and which is kept in constant movement at approx. 28° C. At the proper conditions, there will be an increase in the production of extracellular lentinan, which is shown to be a better immunostimulant than intracellular lentinan. The extracellular product is precipitated from the growth medium by means of methods for the precipitation of microbial polysaccharide.
Owner:MEDIMUSH

Potent immunostimulants from microalgae

Immunostimulatory polysaccharides can be preferentially extracted from food-grade microalgae using an aqueous ethanol extraction procedure. The resulting preparations exhibit extremely potent immunostimulatory activity. The preferential extraction of these immunostimulatory polysaccharides is dependent on the concentration of ethanol used and the extraction temperature. The most efficient conditions are 50% ethanol concentration at temperatures between 60° and 70° C. The isolated polysaccharide preparations are potentially useful as a botanical or pharmaceutical preparation to improve immune function.
Owner:MISSISSIPPI UNIV OF
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products